Taisho Pharmaceutical Holdings
GPTKB entity
Properties (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Tsumura_&_Co.
|
| gptkbp:brand |
Alinamin
Soflan Soflan C Soflan S Pabron |
| gptkbp:CEO |
gptkb:Akira_Matsumoto
|
| gptkbp:employees |
Approximately 3,000
|
| gptkbp:founded |
1912
|
| gptkbp:headquarters |
gptkb:Tokyo,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Taisho Pharmaceutical Holdings
|
| gptkbp:market |
gptkb:Japan
|
| gptkbp:partnerships |
Various international pharmaceutical companies
|
| gptkbp:philanthropy |
Disaster relief efforts
Educational programs Community support programs Health and wellness initiatives |
| gptkbp:products |
Over-the-counter drugs
|
| gptkbp:research_focus |
Prescription drugs
Health supplements OTC pharmaceuticals |
| gptkbp:revenue |
¥200 billion (2020)
|
| gptkbp:stockExchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:subsidiary |
gptkb:Taisho_Pharmaceutical_Co.,_Ltd.
|
| gptkbp:sustainability |
Energy efficiency measures
Environmental initiatives Waste reduction programs Sustainable sourcing Carbon footprint reduction |
| gptkbp:type |
Public company
|
| gptkbp:website |
www.taisho-holdings.co.jp
|